MyFinsight
Home
Blog
About
Contact
Download
Download image
Gross proceeds from
initial public offering...
$160,425K
Proceeds from exercise of
stock options
$55K
Net cash provided by
financing activities
$157,755K
Canceled cashflow
$2,725K
Net increase in cash
and cash...
$142,544K
Canceled cashflow
$15,211K
Payments for deferred
initial public offering...
$2,725K
Stock-based compensation
$1,675K
Accounts payable
$953K
Depreciation expense
$318K
Non-cash lease expense
$63K
Lease liability
$25K
Redemptions of short-term
investments
$3,009K
Net cash used in
operating activities
-$13,544K
Net cash used in
investing activities
-$1,667K
Canceled cashflow
$3,034K
Canceled cashflow
$3,009K
Net loss
-$13,818K
Purchases of short-term
investments
$4,000K
Payroll-related accruals
-$1,300K
Prepaid expenses and
other current assets
$805K
Other non-current
assets
$298K
Other receivables
$222K
Other current
liabilities
-$104K
Interest receivable
$31K
Property and equipment
$676K
Back
Back
Cash Flow
SpyGlass Pharma, Inc. (SGP)
SpyGlass Pharma, Inc. (SGP)
source: myfinsight.com